Li Marzi Vincenzo, Morselli Simone, Di Maida Fabrizio, Musco Stefania, Gemma Luca, Bracco Francesco, Tellini Riccardo, Vittori Gianni, Mari Andrea, Campi Riccardo, Carini Marco, Serni Sergio, Minervini Andrea
Unit of Urological Robotic Surgery and Renal Transplantation, Careggi Hospital, Ospedale Careggi, Largo Brambilla 3, Florence 50134, Italy.
Unit of Urological Robotic Surgery and Renal Transplantation, Careggi Hospital, Florence, Italy.
Ther Adv Urol. 2022 Apr 21;14:17562872221090884. doi: 10.1177/17562872221090884. eCollection 2022 Jan-Dec.
Robotic sacrocolpopexy (RSCP) is an established option for the treatment of apical, anterior, and proximal posterior compartment pelvic organ prolapses (POP). However, there is lack of evidence investigating how lower bowel tract symptoms (LBTS) may change after RSCP.
Data from consecutive patients treated with RSCP for stage 3 or higher POP from 2012 to 2019 at a single tertiary referral center with at least 1 year of follow-up were prospectively collected and retrospectively analyzed. RSCP was performed following a standardized technique which always employed both anterior and posterior hand-shaped meshes. Outcomes were collected at follow-up and analyzed. LBTS were evaluated through the Wexner questionnaire.
Overall, 114 women underwent RSCP. Eleven were excluded for missing data, whereas 12 had insufficient follow-up. Thus, 91 (79.8%) patients were included in this cohort. Median follow-up was 42 [interquartile range (IQR), 19-62] months. Mean age was 65 ± 10 years. In our series, RSCP was mainly performed for anterior and apical/medium stage 3 POP (in 95.6% of patients). Anatomic success rate of RSCP was 97.8%, with 89 patients with POP stage 0-1 at 12-month follow-up. Two patients (2.2%) experienced POP recurrence and were treated with redo-SCP. No patient experienced clinically significant posterior vaginal wall prolapse after RSCP. When analyzing LBTS, there was no significant change in postoperative total Wexner's score as compared to the preoperative value ( > 0.05). However, the manual assistance subscore was statistically significantly lower within the first-year follow-up ( = 0.04), but it spontaneously improved during the follow-up ( = 0.12).
RSCP with simultaneous placement of both anterior and posterior mesh is safe and successful to treat high-stage POP in carefully selected patients. Of note, LBTS appear unaffected by posterior mesh placement, supporting its routine use to prevent posterior POP recurrence. Larger prospective studies are needed to confirm our results.
机器人骶骨阴道固定术(RSCP)是治疗盆腔器官脱垂(POP)的顶端、前部和近端后部腔室脱垂的既定选择。然而,缺乏关于RSCP后下肠道症状(LBTS)如何变化的证据。
前瞻性收集并回顾性分析了2012年至2019年在单一三级转诊中心接受RSCP治疗3期或更高期POP且至少随访1年的连续患者的数据。RSCP采用标准化技术进行,该技术始终使用前后手形网片。在随访时收集并分析结果。通过韦克斯纳问卷评估LBTS。
总体而言,114名女性接受了RSCP。11名因数据缺失被排除,12名随访不足。因此,该队列纳入了91名(79.8%)患者。中位随访时间为42[四分位间距(IQR),19 - 62]个月。平均年龄为65±10岁。在我们的系列研究中,RSCP主要用于治疗前部和顶端/中度3期POP(95.6%的患者)。RSCP的解剖学成功率为97.8%,12个月随访时有89名患者处于POP 0 - 期。两名患者(2.2%)经历了POP复发并接受了再次SCP治疗。RSCP后没有患者出现临床上显著的阴道后壁脱垂。在分析LBTS时,术后总韦克斯纳评分与术前值相比无显著变化(>0.05)。然而,人工辅助子评分在第一年随访期间在统计学上显著较低(=0.04),但在随访期间自发改善(=0.12)。
同时放置前后网片的RSCP在精心挑选的患者中治疗高期POP是安全且成功的。值得注意的是,LBTS似乎不受后网片放置的影响,支持其常规用于预防后POP复发。需要更大规模的前瞻性研究来证实我们的结果。